Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TLSA | 6-K | neutral | 3/10 | Tiziana Life Sciences announced a poster presentation on the Phase 2a BANYAN trial of intranasal foralumab in ALS at the | Aug 24, 2026 |
| INCR | 6-K | bullish | 7/10 | InterCure finalized a NIS 230M (~$77M) settlement with Israeli authorities for war-related indirect damages from the Oct | Aug 24, 2026 |
| ANIP | 8-K | neutral | 2/10 | ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, and announced the res | Aug 24, 2026 |
| DTIL | 8-K | bullish | 7/10 | Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duc | Aug 24, 2026 |
| MESO | 6-K | neutral | 3/10 | Mesoblast filed a 6-K announcing a webcast to discuss operational highlights and financial results for the full year end | Aug 24, 2026 |
| VRXA | 6-K | neutral | 3/10 | Veraxa Biotech announced initial positive in vitro proof-of-concept results from its strategic research collaboration wi | Aug 24, 2026 |
| ADIA | 8-K | neutral | 3/10 | Adia Nutrition, Inc. entered into an engagement letter with Lucosky Brookman LLP for legal services related to a planned | Aug 24, 2026 |
| JUNS | 424B5 | bearish | 7/10 | Jupiter Neurosciences is raising approximately $1.74 million in net proceeds through a registered direct offering of 307 | Aug 24, 2026 |
| AVXL | DEFA14A | mixed | 7/10 | Anavex Life Sciences Corp. filed a DEFA14A on August 24, 2026, mailing a stockholder letter regarding the 2026 Annual Me | Aug 24, 2026 |
| JUNS | 8-K | bearish | 6/10 | Jupiter Neurosciences priced a ~$2.0M registered direct offering of 307,692 shares at $6.50/share, with D. Boral Capital | Aug 24, 2026 |
| ERAS | 8-K | bullish | 5/10 | Erasca announced that the FDA granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of metastatic pancreat | Aug 24, 2026 |
| CAPR | 8-K | bearish | 7/10 | Capricor Therapeutics announced that the FDA extended the PDUFA target action date for its Deramiocel BLA from August 22 | Aug 24, 2026 |
| BCDA | 8-K | bullish | 6/10 | BioCardia announced that the FDA has confirmed and accepted the meeting minutes from its May 2026 Pre-Submission Meeting | Aug 24, 2026 |
| SPRC | 6-K | neutral | 3/10 | SciSparc announced via press release that its subsidiary NeuroThera's collaboration with Clearmind Medicine has achieved | Aug 24, 2026 |
| FBLG | 8-K | neutral | 3/10 | FibroBiologics appointed Leigh Steinberg, a prominent sports agent and longtime advocate for human longevity and brain h | Aug 24, 2026 |
| BAK | 6-K | bearish | 8/10 | Braskem's Board of Directors approved filing for extrajudicial reorganization (a Brazilian restructuring proceeding) cov | Aug 24, 2026 |
| BBIO | INST-CLUSTER | mixed | 6/10 | BridgeBio Pharma saw a mixed institutional cluster in Q2 2026, with 33 buyers adding $561.6M in net new positions (led b | Aug 22, 2026 |
| CPRX | INST-CLUSTER | mixed | 5/10 | CPRX saw a mixed institutional cluster in Q2 2026: 23 buyers added $226.9M in new positions (led by JPMorgan, American C | Aug 22, 2026 |
| LQDA | CLUSTER | neutral | 4/10 | Two insiders at Liquidia Corp sold a combined $6.46M in open-market sales within a week of the company's Q2 2026 earning | Aug 22, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two insiders at Arcutis Biotherapeutics sold a combined $170K in open-market sales over a week. Director Welgus Howard G | Aug 22, 2026 |
| ZLAB | CLUSTER | neutral | 2/10 | Two Zai Lab insiders, Director William Lis and CFO Yajing Chen, sold a combined $220K in open-market sales over an 8-day | Aug 22, 2026 |
| FDMT | CLUSTER | neutral | 3/10 | CEO David Kirn and CLO Scott Bizily sold a combined ~$683K in open-market sales after exercising stock options. The CEO' | Aug 22, 2026 |
| CAMP | CLUSTER | bearish | 4/10 | Two Camp4 insiders, Director Andrew Schwab and CSO Daniel Tardiff, sold a combined $223K in open-market sales on August | Aug 22, 2026 |
| TWST | CLUSTER | neutral | 4/10 | Four Twist Bioscience insiders, including CEO Emily Leproust and President/COO Patrick Finn, sold a total of $8.48M in s | Aug 22, 2026 |
| KURA | CLUSTER | bullish | 6/10 | Kura Oncology CEO Troy Wilson purchased $1.11M of stock on the open market at $11.12/share, while Chief Legal Officer Te | Aug 22, 2026 |
| TAK | CLUSTER | neutral | 2/10 | Two Takeda insiders, the President of R&D and the Chief Human Resources Officer, sold a combined $598K in open-market sa | Aug 22, 2026 |
| ELAN | CLUSTER | bullish | 4/10 | Two Elanco insiders, Director Lawrence Kurzius and GC/Corp Sec Shiv O'Neill, made open-market purchases totaling $1.03M | Aug 22, 2026 |
| MEDP | CLUSTER | neutral | 3/10 | A two-insider cluster at Medpace shows net selling of $4.69M, dominated by Director Fred B. Davenport Jr.'s open-market | Aug 22, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$1.54M in open-market sales on August 20, 2026, following the | Aug 22, 2026 |
| PTCT | CLUSTER | neutral | 2/10 | Two insiders at PTC Therapeutics sold a total of $459K in open-market sales over a 7-day window. Director Michael Schmer | Aug 22, 2026 |